Advanced Search
DSpace@MIT

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.author Cetin, Arif Engin
dc.contributor.author Stevens, Mark M.
dc.contributor.author Calistri, Nicholas L
dc.contributor.author Olcum, Selim A.
dc.contributor.author Kimmerling, Robert John
dc.contributor.author Manalis, Scott R
dc.date.accessioned 2017-11-28T20:49:38Z
dc.date.available 2017-11-28T20:49:38Z
dc.date.issued 2017-11
dc.date.submitted 2017-08
dc.identifier.issn 2041-1723
dc.identifier.uri http://hdl.handle.net/1721.1/112320
dc.description.abstract Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse. Consequently, methods to select the most efficacious therapy are of great interest. Here we utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (MAR). We show that MAR accurately and rapidly defines therapeutic susceptibility across human multiple myeloma cell lines to a gamut of standard-of-care therapies. Finally, we demonstrate that our MAR assay, without the need for extended culture ex vivo, correctly defines the response of nine patients to standard-of-care drugs according to their clinical diagnoses. This data highlights the MAR assay in both research and clinical applications as a promising tool for predicting therapeutic response using clinical samples. en_US
dc.publisher Nature Publishing Group en_US
dc.relation.isversionof http://dx.doi.org/10.1038/s41467-017-01593-2 en_US
dc.rights Creative Commons Attribution 4.0 International en_US
dc.rights.uri https://creativecommons.org/licenses/by/4.0/ en_US
dc.title Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation en_US
dc.type Article en_US
dc.identifier.citation Cetin, Arif E. et al. “Determining Therapeutic Susceptibility in Multiple Myeloma by Single-Cell Mass Accumulation.” Nature Communications 8, 1 (November 2017): 1613 © 2017 The Author(s) en_US
dc.contributor.department David H. Koch Institute for Integrative Cancer Research at MIT en_US
dc.contributor.department Massachusetts Institute of Technology. Department of Biological Engineering en_US
dc.contributor.department Massachusetts Institute of Technology. Department of Mechanical Engineering en_US
dc.contributor.mitauthor Cetin, Arif Engin
dc.contributor.mitauthor Stevens, Mark M.
dc.contributor.mitauthor Calistri, Nicholas L
dc.contributor.mitauthor Olcum, Selim A.
dc.contributor.mitauthor Kimmerling, Robert John
dc.contributor.mitauthor Manalis, Scott R
dc.relation.journal Nature Communications en_US
dc.identifier.mitlicense PUBLISHER_CC en_US
dc.eprint.version Final published version en_US
dc.type.uri http://purl.org/eprint/type/JournalArticle en_US
eprint.status http://purl.org/eprint/status/PeerReviewed en_US
dc.date.updated 2017-11-28T20:09:57Z
dspace.orderedauthors Cetin, Arif E.; Stevens, Mark M.; Calistri, Nicholas L.; Fulciniti, Mariateresa; Olcum, Selim; Kimmerling, Robert J.; Munshi, Nikhil C.; Manalis, Scott R. en_US
dspace.embargo.terms N en_US
dc.identifier.orcid https://orcid.org/0000-0002-3978-8478
dc.identifier.orcid https://orcid.org/0000-0002-5702-8667
dc.identifier.orcid https://orcid.org/0000-0002-6417-1007
dc.identifier.orcid https://orcid.org/0000-0001-9939-764X
dc.identifier.orcid https://orcid.org/0000-0001-5223-9433


Files in this item

Name Size Format
Downloadable Full Text - PDF

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International
Open Access